|
|
The Body Covers:
The 8th Conference on Retroviruses and Opportunistic Infections
Sheraton Chicago Hotel and Towers, Chicago, Illinois
February 4-8, 2001
The 8th Conference on Retroviruses and Opportunistic Infections draws 3,200 clinicians and basic scientists from around the world to present the latest research on HIV, AIDS, and opportunistic infections. The meeting is sponsored by the Foundation for Retrovirology and Human Health and is in scientific collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC).
The Retrovirus Conference, regarded as one of the most important scientific gatherings of the year, was created to provide a forum for scientists and clinicians to present, discuss, and critique developments in the field of human retrovirology and related opportunistic complications. The subjects that will be highlighted are: virology, pathogenesis, host-virus interactions, pathology, immunology, epidemiology, diagnostics, prevention, therapy, pharmacology, and vaccines. In addition, new scientific studies concerning the diagnosis, treatment, and prevention of associated opportunistic infections will be included.
Reporting exclusively for The Body are Brian Boyle, M.D., J.D.; Calvin Cohen, M.D., M.S.; Richard Alan Elion, M.D.; Judith Feinberg, M.D.; Keith Henry, M.D.; Andrew T. Pavia, M.D.; Paul E. Sax, M.D.; Pablo Tebas, M.D.; and Benjamin Young, M.D., Ph.D. For more information on these outstanding doctors, click on their pictures or on their names.
Funding for this conference coverage at The Body is provided, in part, by unrestricted educational grants from Bristol-Myers Squibb Company, DuPont Pharmaceuticals Company, Glaxo Wellcome Inc., Merck & Co., Inc. and Roxane Laboratories, Inc.
| The Body's Conference Summaries |
Day One
Monday,
February 5 | Day Two
Tuesday,
February 6 | Day Three
Wednesday,
February 7 | Day Four
Thursday,
February 8 |
|
Viral Reservoirs and Ongoing Virus Replication in Patients on HAART
NeuroAIDS
Antiretroviral Chemotherapy I
Co-Pathogens and Opportunistic Infections
Immunology: Miscellaneous
CD4 and CD8 T-Cell Responses
Factors Associated with Disease Progression
Risky Behaviors/Detection of Infection
Transmission
Post-Exposure Prophylaxis
Diagnostics
Pharmacology of Antiviral Chemotherapeutic Agents
|
HIV-Related Peripheral Neuropathies and Their Treatment
Epidemiology and Infection Control
Maternal-Fetal Transmission of HIV-1: Implications for Care of HIV-Affected Women and Children
Structured Treatment Interruption: Novel Strategy or Oxymoron
Trends in Morbidity and Mortality
Antiretroviral Chemotherapeutic Agents: Preclinical Studies
Clinical Trials of HIV-1 Reverse Transcriptase Inhibitors
Clinical Trials of HIV-1 Protease Inhibitors
Antiretroviral Chemotherapy: When to Start
Immune-Based Therapy
Treatment Interruption
Immune Reconstitution
Viral Dynamics and Reservoirs
Treatment of Primary Infection
Clinical, Viral, and Immunological Features of Primary Infection
Drug Resistance in Primary Infection
Regimen Failure
Clinical Utility of Resistance Testing
Resistance to Antiretroviral Drugs
HIV Pathogenesis
|
Development of CCR5 Antagonists as a New Class of Anti-HIV Therapeutic
Antiretroviral Chemotherapy II
Viral Reservoirs
Metabolic Complications of HIV-1 Disease
HCV Co-Infection
HHV-8 and Kaposi's Sarcoma
CNS Reservoirs
Hyperlactatemia, Hepatotoxicity, and Other Adverse Effects of Antiretroviral Therapies
Osteopenia and Bone Metabolism Disorders
Abnormalities of Fat Distribution and Insulin Resistance
Cardiovascular Disease Risk
Antiretroviral Switch Studies for Metabolic Complications
Antiretroviral Therapy in Treatment-Naive and -Experienced Children
Immune Reconstitution in Children
Perinatal Transmission: Trends in Use of Preventive Interventions
Drug-Drug Interactions
Pharmacokinetics of Antiretroviral Drugs
Primary Infection
|
Advances in Antiretroviral Chemotherapeutics
Controlled Phase II Trial Assessing Three Doses of T-20 in Combination with Abacavir, Amprenavir, Low-Dose Ritonavir, and Efavirenz
HAART-Associated Bone Mineral Loss Through Increased Rate of Bone Turnover in Vertically HIV-Infected Children
|
|
Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
|
|
|
